<code id='F7E87463B5'></code><style id='F7E87463B5'></style>
    • <acronym id='F7E87463B5'></acronym>
      <center id='F7E87463B5'><center id='F7E87463B5'><tfoot id='F7E87463B5'></tfoot></center><abbr id='F7E87463B5'><dir id='F7E87463B5'><tfoot id='F7E87463B5'></tfoot><noframes id='F7E87463B5'>

    • <optgroup id='F7E87463B5'><strike id='F7E87463B5'><sup id='F7E87463B5'></sup></strike><code id='F7E87463B5'></code></optgroup>
        1. <b id='F7E87463B5'><label id='F7E87463B5'><select id='F7E87463B5'><dt id='F7E87463B5'><span id='F7E87463B5'></span></dt></select></label></b><u id='F7E87463B5'></u>
          <i id='F7E87463B5'><strike id='F7E87463B5'><tt id='F7E87463B5'><pre id='F7E87463B5'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          leisure time

          author:fashion    - browse:2
          Rachel Haurwitz of Caribou Biosciences
          Rachel Haurwitz, CEO of Caribou Biosciences. Elizabeth D. Herman for STAT

          Caribou Biosciences said Thursday that its off-the-shelf CAR-T therapy induced durable, complete remissions in patients with advanced B-cell lymphoma that move it closer to the benchmarks set by more established, patient-specific CAR-T therapies.

          In an update to an early-stage study, 44% of the 16 patients treated with Caribou’s on-demand therapy, called CB-010, achieved a complete remission lasting a minimum of six months — a key threshold of durability.

          advertisement

          The CB-010 result is still preliminary, but it begins to compare favorably to currently approved CAR-T therapies, which must be custom made for each patient and have shown durable remission rates in the range of 36-40%, said Caribou CEO Rachel Haurwitz.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          explore